With a track record of over 25 years in value-added analytics for HCPs, biopharmaceutical industry relies on Cygnus Technologies to develop robust, broadly reactive, and qualified HCP immunoassays for many cell expression platforms. From early process development utilizing generic HCP ELISA to long-term and uninterrupted supply of process-specific HCP ELISA critical to QC release testing … Continue reading Considering process-specific HCP Ab and Assay Development?